PMID- 35248497
OWN - NLM
STAT- MEDLINE
DCOM- 20220510
LR  - 20230130
IS  - 1437-7780 (Electronic)
IS  - 1341-321X (Print)
IS  - 1341-321X (Linking)
VI  - 28
IP  - 6
DP  - 2022 Jun
TI  - Adverse effect investigation using application software after vaccination against 
      SARS-CoV-2 for healthcare workers.
PG  - 791-796
LID - S1341-321X(22)00068-X [pii]
LID - 10.1016/j.jiac.2022.02.020 [doi]
AB  - INTRODUCTION: The usefulness of smartphone-based application software as a way to 
      manage adverse events (AEs) after vaccination is well known. The purpose of this 
      study is to clarify the usefulness and precautions of employing a smartphone 
      application for collecting AEs after the administration of Comirnaty(R)️. METHODS: 
      Healthcare workers (HCWs) who were vaccinated with Comirnaty(R)️ were asked to 
      register for the application software and to report AEs for 14 days after 
      vaccination. AEs were self-reported according to severity. The software was set 
      to output an alert in case of fever. RESULTS: The number of HCWs who received the 
      first dose was 2,551, and 2,406 (94.3%) reported their vaccinations. 2,547 
      received the second dose, and 2,347 (92.1%) reported their vaccinations. With the 
      first dose, the reporting rate stayed above 83.3% until the final day. On the 
      other hand, that of the second dose decreased rapidly after 6 days. The most 
      frequent symptom was "pain at injection site" (more than 70%). Severe AEs were 
      6.6% after the second dose, with 0.6% visiting a clinic. Many AEs peaked on the 
      day after administration and disappeared within 1 week. There were few reports of 
      fever. CONCLUSION: Smartphone applications can be used to collect information on 
      AEs after vaccination. Application settings and dissemination are necessary to 
      maintain the reporting rate of HCWs.
CI  - Copyright (c) 2022 Japanese Society of Chemotherapy and The Japanese Association 
      for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
FAU - Yamazaki, Shingo
AU  - Yamazaki S
AD  - Division of Pharmacy, Chiba University Hospital, Chiba, Japan. Electronic 
      address: s-yamazaki@chiba-u.jp.
FAU - Watanabe, Kenta
AU  - Watanabe K
AD  - Division of Pharmacy, Chiba University Hospital, Chiba, Japan.
FAU - Okuda, Yoshio
AU  - Okuda Y
AD  - Division of Infection Control, Chiba University Hospital, Chiba, Japan.
FAU - Urushihara, Misao
AU  - Urushihara M
AD  - Division of Infection Control, Chiba University Hospital, Chiba, Japan.
FAU - Koshikawa, Hiromi
AU  - Koshikawa H
AD  - Division of Infection Control, Chiba University Hospital, Chiba, Japan; Chiba 
      University Hospital COVID-19 Vaccine Center, Chiba University, Japan.
FAU - Chiba, Hitoshi
AU  - Chiba H
AD  - Division of Infection Control, Chiba University Hospital, Chiba, Japan.
FAU - Yahaba, Misuzu
AU  - Yahaba M
AD  - Division of Infection Control, Chiba University Hospital, Chiba, Japan.
FAU - Taniguchi, Toshibumi
AU  - Taniguchi T
AD  - Division of Infection Control, Chiba University Hospital, Chiba, Japan.
FAU - Nakada, Taka-Aki
AU  - Nakada TA
AD  - Department of Emergency and Critical Care Medicine, Graduate School of Medicine, 
      Chiba University, Japan.
FAU - Nakajima, Hiroshi
AU  - Nakajima H
AD  - Department of Allergy and Clinical Immunology, Chiba University Hospital, Chiba, 
      Japan; Chiba University Hospital COVID-19 Vaccine Center, Chiba University, 
      Japan.
FAU - Ishii, Itsuko
AU  - Ishii I
AD  - Division of Pharmacy, Chiba University Hospital, Chiba, Japan.
FAU - Igari, Hidetoshi
AU  - Igari H
AD  - Division of Infection Control, Chiba University Hospital, Chiba, Japan; Chiba 
      University Hospital COVID-19 Vaccine Center, Chiba University, Japan.
LA  - eng
PT  - Journal Article
DEP - 20220301
PL  - Netherlands
TA  - J Infect Chemother
JT  - Journal of infection and chemotherapy : official journal of the Japan Society of 
      Chemotherapy
JID - 9608375
RN  - 0 (COVID-19 Vaccines)
SB  - IM
MH  - *COVID-19/prevention & control
MH  - COVID-19 Vaccines/*adverse effects
MH  - *Drug-Related Side Effects and Adverse Reactions
MH  - Health Personnel
MH  - Humans
MH  - SARS-CoV-2
MH  - Software
MH  - Vaccination/adverse effects
PMC - PMC8885303
OTO - NOTNLM
OT  - Adverse event
OT  - Application software
OT  - SARS-CoV2
OT  - Vaccine
COIS- Taka-aki Nakada (TN) is an inventor and has submitted patents related to 
      respon:sum system. TN serves as CEO, receives executive compensation and holds 
      shares in Smart119 Inc., which develops the respon:sum system.
EDAT- 2022/03/07 06:00
MHDA- 2022/05/11 06:00
PMCR- 2022/03/01
CRDT- 2022/03/06 20:28
PHST- 2021/11/16 00:00 [received]
PHST- 2022/02/02 00:00 [revised]
PHST- 2022/02/23 00:00 [accepted]
PHST- 2022/03/07 06:00 [pubmed]
PHST- 2022/05/11 06:00 [medline]
PHST- 2022/03/06 20:28 [entrez]
PHST- 2022/03/01 00:00 [pmc-release]
AID - S1341-321X(22)00068-X [pii]
AID - 10.1016/j.jiac.2022.02.020 [doi]
PST - ppublish
SO  - J Infect Chemother. 2022 Jun;28(6):791-796. doi: 10.1016/j.jiac.2022.02.020. Epub 
      2022 Mar 1.